Interní Med. 2006; 8(9): 389-392

PREVENTION AND TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS

MUDr. Michal Scheinost, prof. MUDr. Karel Pavelka DrSc, MUDr. Simona Skácelová, MUDr. Gabriela Šimková, MUDr. Radka Svobodová
Revmatologický ústav, Praha

Glucocorticosteroid-induced osteoporosis (GIOP) is a chronic disabling disease with high mortality, common social isolation of the patients, and last, but not least, astronomical economic consequences. GIOP is the most frequent of all secondary types of osteoporosis owing to their widespread use. The safe dose of glucocorticoid does not exist, that is why every administration of prednison or its equivalent in a dose of 5 mg and more for a period of 3 months should be complemented with preventive calcium and vitamin D suplementation. The prevention of GIOP is essential but the prescribing of preventive medication for corticosteroid induced loss of bone is still very low. In view of this fact the autors make an effort to increase frequency of decision to prevent steroid induced osteoporosis in daily clinical practice.

Keywords: Key words: glucocorticosteroid-induced osteoporosis, prevention, treatment, risk factors.

Published: March 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Scheinost M, Pavelka K, Skácelová S, Šimková G, Svobodová R. PREVENTION AND TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS. Interní Med. 2006;8(9):389-392.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Canalis E. Mechanism of glucocorticoid-induced osteoporosis. Curr Opin Rheumatol 2003; 15 (4): 454-457. Go to original source... Go to PubMed...
    2. Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D. Risk of mortality following clinical fractures. Osteoporos Int 2000; 11: 556-561. Go to original source... Go to PubMed...
    3. Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA. Mortality after all major types of osteoporotic fracture in men and woman: An observational study. Lancet 1999; 353: 878-882. Go to original source... Go to PubMed...
    4. Cooper C. Epidemiology of osteoporosis. Osteoporos Int 1999; 9 (Suppl 2): S2-8. Go to original source... Go to PubMed...
    5. Curtis JR, Westfall AO, Allison JJ, et al. Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients. Arthritis Rheum 2005; 52: 2485-2494. Go to original source... Go to PubMed...
    6. Delmas PD, Recker RR, Chesnut CH, et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 2004; 15: 792-798. Go to original source... Go to PubMed...
    7. Gudbjornsson B, Juliusson UI, Gudjonsson FV. Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice. Ann Rheum Dis 2002; 61: 32-36. Go to original source... Go to PubMed...
    8. Johnell O. Risk factors for osteoporosis: an epidemiological overview. Medicographia 2006; 28: 9-12.
    9. Kado DM, Browner WS, Palermo L, Nevitt M, Genant HK, Cummings SR. For the Study of Osteoporotic Fractures Research Group. Vertebral fractures and mortality in older woman: a prospective study. Arch Intern Med 1999; 159: 1215-1220. Go to original source... Go to PubMed...
    10. Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a new fracture. JAMA 2000; 285: 320-323. Go to original source... Go to PubMed...
    11. Reginster JY, Burlet N. Osteoporosis: a still increasing prevalence. Bone 2006; 38: S4-S9. Go to original source... Go to PubMed...
    12. Reginster JY, Adami S, Lakatos P, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 2006; 000: 1-9. Go to original source... Go to PubMed...
    13. Růžičková O, Bayer M, Pavelka K, Palička V. Doporučení pro prevenci a léčbu glukokortikoidy indukované osteoporózy u pacientů s revmatickým onemocněním (Společné stanovisko České revmatologické společnosti a Společnosti pro metabolická onemocnění skeletu). Čes Revmatol 2004; 12: 163-174.
    14. Sambrook PN, Diamond T, Ferris L, et al. Corticosteroid induced osteoporosis - guidelines for the treatment. Australian Family Phisician 2001; 30: (8).
    15. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000; 15: 993-1000. Go to original source... Go to PubMed...
    16. Walsh LJ, Wong CA, Oborne J, et al. Adverse effects of oral corticosteroids in relation to dose in patients with lung disease. Thorax 2001; 56: 279-284. Go to original source... Go to PubMed...
    17. Yood RA, Harrold LR, Fish L, et al. Prevention of glucocorticoid-induced osteoporosis: experience in a managed care setting. Arch Intern Med. 2001; 161: 1322-1327. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.